IDegAsp was superior in lowering fasting plasma glucose ( FPG ) ( ETD -@ mmol/L , @ % CI -@ ; -@ , p < @ ) , and resulted in a lower final mean daily insulin dose ( @ U/kg vs @ U/kg , estimated rate ratio -LSB- RR -RSB- @ , @ % CI @ ; @ , p < @ ) .